Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Medicine and Health Sciences

Reply: There Are Limits To Autonomy., John W C Entwistle, Kathleen N Fenton Jul 2020

Reply: There Are Limits To Autonomy., John W C Entwistle, Kathleen N Fenton

Department of Surgery Faculty Papers

No abstract provided.


The Rice Pentatricopeptide Repeat Protein Ppr756 Is Involved In Pollen Development By Affecting Multiple Rna Editing In Mitochondria., Qiannan Zhang, Yanghong Xu, Jishuai Huang, Kai Zhang, Haijun Xiao, Xiaojian Qin, Linlin Zhu, Yingguo Zhu, Jun Hu Jun 2020

The Rice Pentatricopeptide Repeat Protein Ppr756 Is Involved In Pollen Development By Affecting Multiple Rna Editing In Mitochondria., Qiannan Zhang, Yanghong Xu, Jishuai Huang, Kai Zhang, Haijun Xiao, Xiaojian Qin, Linlin Zhu, Yingguo Zhu, Jun Hu

Department of Medicine Faculty Papers

In land plants, the pentatricopeptide repeat (PPR) proteins form a large family involved in post-transcriptional processing of RNA in mitochondria and chloroplasts, which is critical for plant development and evolutionary adaption. Although studies showed a number of PPR proteins generally influence the editing of organellar genes, few of them were characterized in detail in rice. Here, we report a PLS-E subclass PPR protein in rice, PPR756, loss of function of which led to the abolishment of RNA editing events among three mitochondrial genes including


Targeting Homologous Recombination Addicted Tumors: Challenges And Opportunities, Talia Golan, Jonathan Brody, Md Jan 2020

Targeting Homologous Recombination Addicted Tumors: Challenges And Opportunities, Talia Golan, Jonathan Brody, Md

Kimmel Cancer Center Faculty Papers

Recent advances in next generation sequencing (NGS) and molecular subtyping of tumors have opened the door to clinically available targeted therapies. Although the treatment of many solid tumors still rely on a steady regimen of non-targeted chemotherapeutic agents, it is becoming increasingly more apparent that certain tumors with defects in DNA damage repair (DDR) genes may be exquisitely sensitive to DNA damaging agents or therapies targeting key elements of this pathway such PARP1, ATR, or ATM. Still, for tumors with DDR defects the challenges are multi-fold including: (I) identifying these tumors in patients in time for a window of opportunity …